Screening for dysplasia in patients with longstanding achalasia using chromoendoscopy
Screening for Dysplasia in Longstanding Idiopathic Achalasia: a Prospective Study
This study is testing a new way to use special dye during endoscopy to see if it can help find early signs of cancer in people with long-term achalasia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | KU Leuven Academic / other |
| Locations | 1 site (Leuven) |
| Trial ID | NCT02010983 on ClinicalTrials.gov |
What this trial studies
This study evaluates a screening program that utilizes chromoendoscopy with Lugol dye to detect dysplasia in patients suffering from longstanding achalasia, which significantly increases their risk of developing esophageal squamous cell carcinoma (ESCC). The study aims to improve early diagnosis rates of dysplasia and ESCC, which are often challenging to detect through conventional methods. Additionally, it investigates the relationship between food stasis and the development of dysplasia in these patients. By enhancing detection rates, the study seeks to provide a more effective approach to managing the risks associated with achalasia.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a history of longstanding achalasia for more than 15 years.
Not a fit: Patients with esophageal carcinoma or an allergy to iodine will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and intervention for dysplasia and ESCC in patients with achalasia, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promising results with chromoendoscopy techniques for detecting dysplasia, indicating that this approach is supported by prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * longstanding achalasia (\> 15y) * \> 18y old * informed consent Exclusion Criteria: * allergy to iodine * esophageal carcinoma
Where this trial is running
Leuven
- UZleuven — Leuven, Belgium (Recruiting)
Study contacts
- Study coordinator: an moonen, MD
- Email: an.moonen@med.kuleuven.be
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.